OMER News - Candlesense

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

(NASDAQ:OMER) SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outc...

Clinical trials

4 days ago

Omeros Corporation Reports Second Quarter 2025 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2025, which include...

How sensitive is OMER's stock to changes in biotech sector sentiment or macroeconomic factors given the recent earnings results? Is there any indication of share buyback activity, dividend changes, or other capital allocation moves in response to the earnings? What guidance is management providing for the remainder of FY2025, and how does it align with market expectations?

Earnings

23 days ago

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2025, on Thursday, August 14, 2025, aft...

How might macroeconomic factors or market sentiment impact investor reaction to the Q2 results? Are there any regulatory or clinical trial updates that could materially affect OMER's outlook? What is the cash flow outlook and any planned capital allocation or dividend announcements?

Earnings

26 days ago